JNE Partners LLP

LONDON, null · Quarter end: Sep 30, 2026 · Filed with SEC: Nov 16, 2026 · Open the SEC source ↗
Portfolio Return (1Y)——
Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.$241.5M2026 Q3
Positions5
Top-10 ConcentrationPercent of the portfolio in the 10 largest holdings. High means the fund is concentrated in few stocks.100.0%

JNE Partners LLP reported 5 positions worth $241.5M as of September 30, 2026 (13F filed November 16, 2026). Largest holding: LLYVK (43.2%). Biggest move: exit LBRDAEUR ($21.1M).

5 positions shown
#SymbolCompanyValue ↓% Port.Shares1YYTDSince reported
▸ 1 LLYVKLiberty Live$104.4M43.21%1,073,090——+9.2%
▸ 2 NIQNIQ Global Intelligence$60.8M25.18%3,574,249——+10.4%
▸ 3 LLYVALiberty Live$44.3M18.35%468,121——+9.1%
▸ 4 BIOBio-Rad Laboratories$32.0M13.27%84,817——-4.6%
▸ 5 MLKWFWaldencast$1.9K0.00%333,333———

Read the 2026-Q2 quarterly report · 13F Filing Calendar

🔔 Tell me when this fund files a new 13F

No account needed: in your inbox the morning it is published.

Frequently Asked Questions

What stocks does JNE Partners LLP hold as of Q3 2026?

JNE Partners LLP reported 5 positions worth $241.5M in its Q3 2026 13F filing. Largest positions: LLYVK (43.2%), NIQ (25.2%), LLYVA (18.3%), BIO (13.3%) and MLKWF (0.0%).

What did JNE Partners LLP buy in Q3 2026?

Added to: LLYVA.

What did JNE Partners LLP sell in Q3 2026?

Reduced: LLYVK, NIQ and BIO. Sold out entirely: LBRDAEUR.

13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.